"Aripiprazole" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An antipsychotic agent that is structurally related to piperazines and quinolones. It is a partial agonist of SEROTONIN RECEPTOR, 5-HT1A and DOPAMINE D2 RECEPTORS, where it also functions as a post-synaptic antagonist, and an antagonist of SEROTONIN RECEPTOR, 5-HT2A.
| Descriptor ID |
D000068180
|
| MeSH Number(s) |
D03.383.606.170 D03.633.100.810.835.122
|
| Concept/Terms |
Aripiprazole- Aripiprazole
- 7-(4-(4-(2,3-dichlorophenyl)-1-piperazinyl)butyloxy)-3,4-dihydro-2(1H)-quinolinone
- Aripiprazol
|
Below are MeSH descriptors whose meaning is more general than "Aripiprazole".
Below are MeSH descriptors whose meaning is more specific than "Aripiprazole".
This graph shows the total number of publications written about "Aripiprazole" by people in this website by year, and whether "Aripiprazole" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 0 | 2 | 2 |
| 2020 | 1 | 0 | 1 |
| 2022 | 0 | 1 | 1 |
| 2025 | 2 | 0 | 2 |
| 2026 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Aripiprazole" by people in Profiles.
-
Quality of life in early-phase schizophrenia patients starting treatment with long-acting injectable vs. oral antipsychotic drugs: Data from the European Long-acting Antipsychotics in Schizophrenia Trial (EULAST). Eur Psychiatry. 2026 04 21; 69(1):e51.
-
The effect of switching antipsychotics to aripiprazole versus paliperidone on weight/cardiometabolic parameters: 18-month follow-up findings from the European Long-acting Antipsychotics in Schizophrenia Trial (EULAST). Eur Neuropsychopharmacol. 2026 01; 102:49-57.
-
Subjective well-being in early-phase schizophrenia patients using long-acting injectable versus oral antipsychotic drugs: Data from the European Long-acting Antipsychotics in Schizophrenia Trial (EULAST). Eur Psychiatry. 2025 08 19; 68(1):e116.
-
Legal settlements and the reporting of adverse drug events: Insights from the aripiprazole products liability litigation. Psychiatry Res. 2022 03; 309:114411.
-
Effect of Long-Acting Injectable Antipsychotics vs Usual Care on Time to First Hospitalization in Early-Phase Schizophrenia: A Randomized Clinical Trial. JAMA Psychiatry. 2020 12 01; 77(12):1217-1224.
-
Aripiprazole and atypical neuroleptic malignant syndrome. J Am Acad Child Adolesc Psychiatry. 2004 Dec; 43(12):1457-8.
-
Pharmacology of antipsychotics in the elderly: a focus on atypicals. J Am Geriatr Soc. 2004 Dec; 52(12 Suppl):S258-65.